focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Chariot expects gas in Morocco; Redx wants CFO in US

Tue, 02nd Mar 2021 21:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

All Active Asset Capital Ltd - London-based firm seeking investment opportunities in the technology, software and artificial intelligence space - Exercises first tranche of the option agreement with AAQUA BV, and has acquired 6,000 new AAQUA shares. Under the terms of the option, AAA can subscribe for up to 125,000 new AAQUA ordinary shares at EUR1,000 per share, being a total cost of EUR125 million if fully exercised. AAA paid a EUR1 million fee for the grant of the option to AAQUA in December 2020. The grant fee is offset against the initial exercise cost payable by AAA; and so AAA's incremental cost of this initial exercise is EUR5 million.

----------

Redx Pharma PLC - Macclesfield, England-based treatments for cancer and fibrotic disease - Starts search for US-based chief financial officer. Notes James Mead will continue in his role as CFO until a new appointment has been made at which point Mead will assume the role of chief operating officer. Chair Iain Ross adds: "In conjunction with these changes, Mead will step down from the board with immediate effect and will cease to be a director of the company. Going forward, the board will therefore consist of five non-executive directors and one executive director, the CEO."

----------

Verici Dx PLC - clinical diagnostics developer for organ transplant - Partners Lorenzo Gallon, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, at Henry Ford Health System and Daniel Maluf, at the University of Maryland, Baltimore to collaborate on company's clinical trial surrounding its two lead products, ClaravaTM and TutevaTM, and longer term, the validation of the fibrosis test. "The study uses next generation sequencing in the Verici Dx laboratory to create transcriptomic profiles to validate performance characteristics of the lead Verici Dx immune-phenotype signature tests," company explains.

----------

Amiad Water Systems Ltd - Israel-based water treatment and filtration systems - Launches Spin Klin Nova, a disc filtration system. "This cutting-edge solution, which is the culmination of years of R&D work, is the company's most efficient product to date. It includes multiple new features that are designed to make it as adaptable as possible to the needs of the customer while increasing ease of use," company says. Spin Klin Nova is available now in Israel and will be released globally later this month.

----------

Chariot Oil & Gas Ltd - Africa focused transition energy company - Signs memorandum of understanding along with its partner the Office National des Hydrocarbures et des Mines with the Ministry of Industry, Trade & Green and Digital Economy in Morocco. The MOU relates to the ministry's support of Chariot and ONHYM's Anchois gas development project as a potential provider of significant gas to the Moroccan gas market. Chariot's acting Chief Executive Adonis Pouroulis says: "The signing of this MOU is a significant step in our efforts to access the Moroccan gas markets. With the Kingdom of Morocco's support we intend to build on the positive conversations we are already having with entities involved in the Moroccan gas market, giving us greater confidence that we will sign the necessary agreements to expedite the development of this value accretive gas project, for the benefit of the Kingdom and Chariot's investors."

----------

Hurricane Energy PLC - Surrey-based oil and gas company - Says discussions on Lancaster field forward work programme, strategy, financing and balance sheet recapitalisation are ongoing. Looking at drilling the side-track in 2022 following further planning activity during 2021; or drilling the side-track together with the previously contemplated water injection well as a combined programme in 2022. If those do not pan out, considering drilling the side-track in 2022 and the water injection well in 2023. Hurricane adds: "Proposed side-track is more complex in nature than previous wells on Lancaster due to the incorporation of an intelligent completion and the challenges of delivering the well trajectory from the side-track location."

----------

Tern PLC - internet of things-focused investor - Pleased with recent momentum of portfolio companies. Notes Device Authority Ltd, Talking Medicines Ltd and Wyld Networks Ltd have had a good start to 2021 and have "promising" pipelines of business. Chief Executive Al Sisto says: "Device Authority's IoT summit last week, funded by its partner sponsors, was a particular milestone for the company, demonstrating the depth of their relationships and the important position their KeyScaler product has in the IoT. I wholly endorse one speaker from a global software company who commented that KeyScaler is 'the glue that holds the IoT together'." Adds: "I would also like to congratulate Talking Medicines on being selected as part of Healthcare UK's 'Fast 100'. This recognises Talking Medicines' innovation and their commitment to global expansion."

----------

Mkango Resources Ltd - explorer for rare earth elements in Malawi - Completes flotation pilot plant programme for the Songwe Hill rare earths project in Malawi. The results of the flotation pilot programme will be announced in due course, and the flotation concentrate produced will be supplied to ANSTO in Australia for hydrometallurgical piloting. "Discussions in relation to sites for a rare earth separation plant are ongoing - this will process the high grade, purified mixed rare earth carbonate produced at Songwe, enriched in high value neodymium, praseodymium, dysprosium and terbium," company adds.

----------

IXICO PLC - AI data analytics company - Says Cyclerion Therapeutics Inc, a new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging, diffusion MRI, resting state functional MRI and arterial spin labelling. "Whilst this contract does not change management's expectations of financial performance for the year, it adds to the company's strong order book, further increases visibility of future revenues, and reflects an increasing diversification of the company's client base," company adds.

----------

Westmount Energy Ltd - South America-focused energy investor - Notes the Stena Carron drillship is moving from the Bulletwood-1 location on the Canje block, offshore Guyana, to a new drilling location on the Stabroek block. "Westmount is not a direct participant in the Canje Joint Venture and is therefore not aware of the outcome of the Bulletwood-1 well. The company awaits confirmation and disclosure of the Bulletwood-1 drilling results by the operator or other Canje JV partners. It is the company's intention to update the market as soon as these drilling results are publicly available," company adds. Company plans drilling of the second and third wells on the Canje block, Jabillo-1 and Sapote-1, over the coming months.

----------

Bahamas Petroleum Co - Caribbean and Atlantic margin focused oil and gas company - Notes Honourable Justice Petra Hanna-Weekes allowed the company's application and ordered the applicants to post USD200,000 security for costs within 30 days, pending which the proceedings will be stayed. BPC recently added as a respondent to the application brought by environmental groups against the government of the Bahamas. BPC was entitled to request that the applicants provide security for costs.

----------

Enteq Upstream PLC - oil & gas drilling technology company based in Buckinghamshire - Launches disruptive alternative to traditional rotary steerable systems. The SABER tool is now ready for next stage field trials. "The SABER tool uses internally directed pressure differentials to steer from the drill bit face, delivering true 'at-bit' geo-steering. This mechanically simple design also removes the need for traditional pistons and pads that are susceptible to reliability issues - an approach which can create a smoother and more precise wellbore with easy to manage directional control. SABER will offer a robust, reliable, simple and cost effective directional drilling alternative to current RSS options," Enteq explains.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Signs letter of intent with Thai Airways under which the parties have agreed to amend the existing lease terms. The new terms provide for a "power by the hour" arrangement until the end of next year, with scaled back monthly lease payments thereafter, reflecting the reduced rates now seen in the market. The lease term will be extended from October 2026 to December 2029, with the company retaining a right of early termination in October 2026. Agrees with Thai lenders to amend and restate the existing loan facility agreements in respect of the Thai assets.

----------

Mobile Streams PLC - mobile content and data intelligence company headquartered in London - Says Chinese language version of Streams will launch on March 14. Streams China is aimed specifically at the Chinese market for companies that want to sell their products and services to a western audience. Also notes revenues and customer growth continue to remain ahead of internal forecasts, and monthly Streams Data revenue has now exceeded the net revenue brought in via the legacy business. Says Streams SaaS platform which generated initial customer revenues in October, now generating monthly revenue of GBP12,000, up 33% year on year. "Whilst still at a modest level, with our pipeline of product development and marketing, we expect to see significant growth in 2021, with additional higher price points to come," company adds.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
13 Dec 2022 15:53

UK earnings, trading statements calendar - next 7 days

Wednesday 14 December 
Cohort PLCHalf Year Results
CyanConnode Holdings PLCHalf Year Results
Foresight Sustainable Forestry Co PLCFull Year Results
IntegraFin Holdings PLCFull Year Results
SThree PLCTrading Statement
Tui AGFull Year Results
Watches of Switzerland Group PLCHalf Year Results
Thursday 15 December 
Biffa PLCHalf Year Results
C4X Discovery Holdings PLCFull Year Results
Currys PLCHalf Year Results
Libertine Holdings PLCHalf Year Results
RWS Holdings PLCFull Year Results
Serco Group PLCTrading Statement
Friday 16 December 
Gore Street Energy Storage Fund PLCHalf Year Results
Hollywood Bowl Group PLCFull Year Results
Monday 19 December 
Thruvision Group PLCHalf Year Results
Tuesday 20 December 
Jersey Electricity PLCFull Year Results
Petrofac LtdTrading Statement
Redx Pharma PLCFull Year Results
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
11 Nov 2022 15:24

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Oct 2022 14:51

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Oct 2022 22:06

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Aug 2022 13:58

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

Read more
3 Aug 2022 17:57

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

Read more
27 Jun 2022 16:01

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

Read more
23 Jun 2022 11:29

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

Read more
16 Jun 2022 16:05

UK earnings, trading statements calendar - next 7 days

Friday 17 June 
Tesco PLCQ1 Results
Monday 20 June 
Associated British Foods PLCQ3 Results
SysGroup PLCFull Year Results
SThree PLCTrading Statement
Tuesday 21 June 
DS Smith PLCFull Year Results
Gear4Music PLCFull Year Results
Monks Investment Trust PLCFull Year Results
Record PLCFull Year Results
Safestore Holdings PLCHalf Year Results
Telecom Plus PLCFull Year Results
Wednesday 22 June 
Berkeley Group Holdings PLCFull Year Results
Liontrust Asset Management PLCFull Year Results
Micro Focus International PLCHalf Year Results
Thursday 23 June 
DeepVerge PLCFull Year Results
First Property Group PLCFull Year Results
Manolete Partners PLCFull Year Results
Naked Wines PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Redx Pharma PLCHalf Year Results
Serco Group PLCTrading Statement
Volex PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jun 2022 10:24

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

Read more
19 May 2022 18:55

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 May 2022 19:37

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

Read more
8 Apr 2022 19:41

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

Read more
5 Apr 2022 21:39

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 11:05

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.